Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUTS1W)

Drug Name

BMS-936557 Drug Info

Synonyms

Anti-CXCL10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Medarex/BMS; Anti-IP-10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Bristol-Myers Squibb/Medarex

Indication

Disease Entry	ICD 11	Status	REF
Immune System disease	4A01-4B41	Phase 2	[1]

Cross-matching ID

TTD Drug ID: DMUTS1W

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting C-X-C motif chemokine 10 (CXCL10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NI-0801	DMRQUH4	Autoimmune diabetes	5A10	Phase 2	[3]
MDX-1100	DM0EZWI	Crohn disease	DD70	Phase 2	[4]
Anti-IP10	DMVRNAO	Crohn disease	DD70	Phase 2	[2]
JT02	DMXTKCR	Inflammatory bowel disease	DD72	Phase 2	[5]
NG-641	DMITVHM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
N-Methylleucine	DM9AGCV	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C motif chemokine 10 (CXCL10)	TTQOVYA	CXL10_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01466374) Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease. U.S. National Institutes of Health.
2	Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50.
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029267)
4	A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1730-9.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
7	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.